$同源康医药-B(0_老虎社区_美港股上老虎

$同源康医药-B(02410)$ 截至2025年12月31日止年度业绩，研发成本约2.44亿元，同比增加3.7%;其他收入及收益3760.9万元，同比增加23.14%

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":548312814444648,"tweetId":"548312814444648","gmtCreate":1774877550889,"gmtModify":1774877552875,"author":{"id":4142510355485370,"idStr":"4142510355485370","authorId":4142510355485370,"authorIdStr":"4142510355485370","name":"股市指路明灯","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":14,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"title":"","html":"<html><head></head><body><p><a href=\"https://laohu8.com/S/02410\">$同源康医药-B(02410)$ </a> 截至2025年12月31日止年度业绩，研发成本约2.44亿元，同比增加3.7%;其他收入及收益3760.9万元，同比增加23.14%</p></body></html>","htmlText":"<html><head></head><body><p><a href=\"https://laohu8.com/S/02410\">$同源康医药-B(02410)$ </a> 截至2025年12月31日止年度业绩，研发成本约2.44亿元，同比增加3.7%;其他收入及收益3760.9万元，同比增加23.14%</p></body></html>","text":"$同源康医药-B(02410)$ 截至2025年12月31日止年度业绩，研发成本约2.44亿元，同比增加3.7%;其他收入及收益3760.9万元，同比增加23.14%","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/548312814444648","repostId":0,"isVote":1,"tweetType":1,"viewCount":339,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["02410"],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":121,"optionInvolvedFlag":false,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}